> ## Content Index
> Fetch the complete content index at: https://www.bioreview.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Grants Priority Review to Chemo-Free BRUKINSA Combo in Untreated MCL
- URL: https://www.bioreview.com/fda-grants-priority-review-to-chemo-free-brukinsa-combo-in-untreated-mcl/
- Published: 2026-11-05T14:09:29.000Z
- Updated: 2026-11-06T14:07:37.000Z
- Description: The FDA has granted Priority Review to a chemotherapy-free BRUKINSA plus rituximab regimen for previously untreated mantle cell lymphoma, backed by a Phase 3 trial showing a 43% cut in the risk of progression or death.
- Author: BioReview Admin
- Tags: Pharmaceuticals, Biotechnology

The U.S. Food and Drug Administration has accepted a supplemental New Drug Application for BRUKINSA (zanubrutinib) given with rituximab in previously untreated mantle cell lymphoma, and it has granted the filing Priority Review. BeOne Medicines Ltd. (Nasdaq: ONC), the global oncology company formerly known as BeiGene, made the [announcement](https://www.businesswire.com/news/home/20261103605806/en/U.S.-FDA-Grants-Priority-Review-to-BeOne-Medicines-BRUKINSA-Combination-in-First-Line-Mantle-Cell-Lymphoma?ref=bioreview.com) on November 3, 2026\. If the combination is approved, it would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated MCL.

Mantle cell lymphoma is a rare, typically aggressive B-cell non-Hodgkin lymphoma. For older adults and others who cannot go to stem cell transplant, the usual start has been mild chemoimmunotherapy, most often bendamustine plus rituximab over six intravenous cycles, with real toxicity attached. Swapping bendamustine for a daily oral BTK inhibitor is the proposed alternative. Two caveats matter up front: zanubrutinib is taken until progression rather than for a fixed number of cycles, and overall survival has not been reported.

### What MANGROVE enrolled and compared

The application rests on the Phase 3 MANGROVE trial (NCT04002297), a global, randomized, open-label [study](https://clinicaltrials.gov/study/NCT04002297?ref=bioreview.com) of 510 patients treated at 157 sites. It is the first Phase 3 trial to test a chemotherapy-free BTK-inhibitor regimen against standard chemoimmunotherapy in the front-line MCL setting. The comparator was bendamustine plus rituximab.

Enrollment was limited to previously untreated MCL patients who were ineligible for stem cell transplantation. Eligibility required age 70 or older, or age 60 to 69 with comorbidities that precluded autologous stem cell transplant.

On the experimental arm, patients received zanubrutinib 160 mg by mouth twice daily plus rituximab, then zanubrutinib alone until disease progression or intolerance. On the comparator arm, patients received bendamustine at 90 mg/m2 on Days 1 and 2 plus rituximab for six cycles, then observation. One regimen is continuous oral kinase inhibition; the other is a defined chemoimmunotherapy course followed by observation.

### A 43 percent cut in progression or death

Zanubrutinib plus rituximab reduced the risk of disease progression or death by 43 percent versus bendamustine plus rituximab (hazard ratio 0.57; 95% CI 0.43 to 0.76; p less than 0.0001). The primary endpoint of progression-free survival, assessed by an independent review committee, was met.

That is a clear progression-free survival result against the gentlest commonly used standard. It is not, on the data released so far, evidence that patients live longer. Overall survival is a key secondary endpoint and has not yet been reported. Full MANGROVE results will be presented at the American Society of Hematology annual meeting, Plenary Scientific Session, on December 13, 2026.

### Chemotherapy-free still means daily therapy

Chemotherapy-free is a meaningful label in a population that has been asked to absorb bendamustine. It is not a pause in treatment. Six cycles of bendamustine plus rituximab are time-limited. Zanubrutinib continues until the disease progresses or the drug cannot be tolerated. Patients would trade a finite intravenous course for an open-ended daily tablet, with the clinic visits and lab monitoring that follow.

Safety in MANGROVE was consistent with the known profiles of both medicines, and no new safety signals were identified. BRUKINSA's known serious risks still include hemorrhage, infections, low blood cell counts, cardiac arrhythmias, second primary malignancies, and liver injury. Those are not theoretical in transplant-ineligible adults, who were enrolled because age or comorbidity already limited what they could tolerate. The trial shows those risks looked like the existing BRUKINSA profile.

Bendamustine, for its part, is not a free pass. Bone marrow suppression, infection risk, and the logistics of infusion are precisely why a chemotherapy-sparing option is being pursued. The choice, if the FDA agrees, is between two active regimens with different shapes, not between treatment and rest.

### A new setting, not a new drug

BRUKINSA is already approved in the United States for relapsed or refractory MCL, chronic lymphocytic leukemia and small lymphocytic lymphoma, Waldenstrom macroglobulinemia, relapsed or refractory marginal zone lymphoma, and relapsed or refractory follicular lymphoma. Front-line use in transplant-ineligible MCL would add a setting, not a new compound. Priority Review shortens the intended FDA review timeline; it does not constitute approval. The first-and-only claim is conditional on that approval. What exists today is a positive Phase 3 progression-free survival comparison against bendamustine plus rituximab in 510 transplant-ineligible patients, a safety description that matches prior experience, and a plenary date.